Literature DB >> 18815566

Effect of storage on p63 immunohistochemistry: a time-course study.

Holly N Burford1, Amy L Adams, Omar Hameed.   

Abstract

One of the problems with immunohistochemistry is that storage of unstained slides can have a detectable negative effect on the intensity of staining for various antigens. This has not been well studied for the p63 antigen. A time-course study was performed to evaluate the effect of storage on the intensity of p63 immunohistochemical staining. Slides from various breast lesions/foci were stained with a p63 antibody on day 0 and after storage at room temperature for 2, 4, and 8 weeks. A p63 intensity score, ranging from 0 to 300, was calculated using the intensity (0, 1, 2, or 3+) and percentage of peripheral myoepithelial cell staining (0% to 100%). There was a progressive decline in the p63 intensity score with time with the differences between day 0 and 2 weeks and 2 and 4 weeks being statistically significant (P=0.037 and 0.001, respectively), whereas that between 4 and 8 weeks was not (P=0.075). These findings confirm a time-dependent decline in p63 immunostaining intensity evident as early as with 2 weeks of storage and still present after 8 weeks. This should be considered in the evaluation of p63 immunostains performed on stored unstained sections, both in diagnostic surgical pathology and in translational research studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18815566     DOI: 10.1097/PAI.0b013e31818110de

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  2 in total

1.  p63 expression in Merkel cell carcinoma predicts poorer survival yet may have limited clinical utility.

Authors:  Galina Y Stetsenko; Jacqueline Malekirad; Kelly G Paulson; Jayasri G Iyer; Renee M Thibodeau; Kotaro Nagase; Miranda Schmidt; Barry E Storer; Zsolt B Argenyi; Paul Nghiem
Journal:  Am J Clin Pathol       Date:  2013-12       Impact factor: 2.493

2.  p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis.

Authors:  Rubeta N Matin; Anissa Chikh; Stephanie Law Pak Chong; David Mesher; Manuela Graf; Paolo Sanza'; Valentina Senatore; Maria Scatolini; Francesca Moretti; Irene M Leigh; Charlotte M Proby; Antonio Costanzo; Giovanna Chiorino; Rino Cerio; Catherine A Harwood; Daniele Bergamaschi
Journal:  J Exp Med       Date:  2013-02-18       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.